Novel Inhalation Therapeutics
Serving High Unmet Medical Needs
Novel molecular structure with optimal particle size for uniform distribution and binding all across lungs
Dosage reduction by 60-70% Improved drug transport efficiency to 80-90%
Convenience of Dosing
Ease of dosing enables higher compliance in patients with compromised lungs elasticity
Novel Formulations of Known Drugs for Effective Dosing
Targeted Delivery to the Site of Action in the Lungs
Precision Manufacturing for Particle Size Optimization
Our Initial Focus: Fungal Infections of the Lungs
Fungal infections of the lung pose significant problems in diagnosis and treatment. They mainly affect people living in certain geographic areas and those with immune deficiency. Their virulence varies from causing no symptoms to causing death.
We are developing novel inhalation therapeutics for treating fungal infections in immunocompromised patients. Our target is fungal infections such as Aspergillosis, Candidiasis, and Cryptococcosis, which account for a majority of the direct health care costs compared to all other fungal diseases.
Our solution is in the form of Dry Powder Inhalation(DPI) medicines for a number of invasive fungal infections, such as below: